WO2009005338A3 - Solid forms ult-i, ult-2 and ult-3 of emtricitabine - Google Patents

Solid forms ult-i, ult-2 and ult-3 of emtricitabine Download PDF

Info

Publication number
WO2009005338A3
WO2009005338A3 PCT/NL2008/000158 NL2008000158W WO2009005338A3 WO 2009005338 A3 WO2009005338 A3 WO 2009005338A3 NL 2008000158 W NL2008000158 W NL 2008000158W WO 2009005338 A3 WO2009005338 A3 WO 2009005338A3
Authority
WO
WIPO (PCT)
Prior art keywords
ult
emtricitabine
solid forms
hiv medicaments
medicaments
Prior art date
Application number
PCT/NL2008/000158
Other languages
French (fr)
Other versions
WO2009005338A2 (en
WO2009005338A8 (en
Inventor
Evanthia Dova
Der Ploeg Ida Van
Original Assignee
Ultimorphix Technologies B V
Evanthia Dova
Der Ploeg Ida Van
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ultimorphix Technologies B V, Evanthia Dova, Der Ploeg Ida Van filed Critical Ultimorphix Technologies B V
Publication of WO2009005338A2 publication Critical patent/WO2009005338A2/en
Publication of WO2009005338A3 publication Critical patent/WO2009005338A3/en
Publication of WO2009005338A8 publication Critical patent/WO2009005338A8/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D411/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms
    • C07D411/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D411/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • AIDS & HIV (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention provides novel crystalline forms of Emtricitabine, designated Emtricitabine form ULT-I, form ULT-2 and ULT-3, methods for the preparation of Emtricitabine form ULT-I, ULT-2 and ULT-3 and the use of Emtricitabine form ULT-I and/or ULT-2 and/or ULT-3 in pharmaceutical applications, in particular in anti-HIV medicaments. The crystalline form of Emtricitabine form ULT-I, ULT-2 and/or ULT-3 can be used in combination with other anti-HIV medicaments such as Efavirenz and Tenofovir DF.
PCT/NL2008/000158 2007-07-05 2008-06-23 Solid forms ult-i, ult-2 and ult-3 of emtricitabine WO2009005338A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US94808607P 2007-07-05 2007-07-05
US60/948,086 2007-07-05

Publications (3)

Publication Number Publication Date
WO2009005338A2 WO2009005338A2 (en) 2009-01-08
WO2009005338A3 true WO2009005338A3 (en) 2009-07-23
WO2009005338A8 WO2009005338A8 (en) 2009-09-11

Family

ID=39865291

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/NL2008/000158 WO2009005338A2 (en) 2007-07-05 2008-06-23 Solid forms ult-i, ult-2 and ult-3 of emtricitabine

Country Status (1)

Country Link
WO (1) WO2009005338A2 (en)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002070518A1 (en) * 2001-03-01 2002-09-12 Triangle Pharmaceuticals, Inc. Polymorphic and other crystalline forms of cis-ftc
WO2007077505A2 (en) * 2005-12-30 2007-07-12 Ranbaxy Laboratories Limited Crystalline l-menthyl (2r, 5s)-5-(4-amino-5-fluoro-2-oxo-2h-pyrimidin-1-yl)[1, 3]oxathiolan-2-carboxylate and process for preparation thereof

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002070518A1 (en) * 2001-03-01 2002-09-12 Triangle Pharmaceuticals, Inc. Polymorphic and other crystalline forms of cis-ftc
WO2007077505A2 (en) * 2005-12-30 2007-07-12 Ranbaxy Laboratories Limited Crystalline l-menthyl (2r, 5s)-5-(4-amino-5-fluoro-2-oxo-2h-pyrimidin-1-yl)[1, 3]oxathiolan-2-carboxylate and process for preparation thereof

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
VAN ROEY P ET AL: "Absolute configuration of the antiviral agent (-)-cis-5-fluoro-1-(2-(hydroxymethyl)-1,3-oxathiolan-5-yl)cytosine", ANTIVIRAL CHEMISTRY & CHEMOTHERAPY, BLACKWELL SCIENTIFIC PUBL., LONDON, GB, vol. 4, no. 6, 1 January 1993 (1993-01-01), pages 369 - 375, XP008089456, ISSN: 0956-3202 *

Also Published As

Publication number Publication date
WO2009005338A2 (en) 2009-01-08
WO2009005338A8 (en) 2009-09-11

Similar Documents

Publication Publication Date Title
WO2009074351A3 (en) Solid forms of tenofovir disoproxil
WO2006132647A3 (en) Antimicrobial copolymers and uses thereof
EP3626253A3 (en) Stable formulations of linaclotide
IL196775A (en) 2,4-bis(3-methyl-morpholin-4-yl)-7-phenyl-pyrido[2,3-d]pyrimidine derivatives, pharmaceutical compositions comprising them and use thereof as medicaments and in the manufacture of medicaments
IL210452A (en) Derivatives of dimethyl-oxo-dihydro-(pyridine-3 or 4-yl)- phenyl- 6- methyl-6 - phenyl -[1,3]- oxazine -2- one, pharmaceutical compositions comprising them and their use in the manufacture of medicaments
IL169647A (en) Hiv replication inhibiting pyrimidines, their use in the preparation of pharmaceutical compositions and pharmaceutical compositions comprising them
PL1792927T3 (en) Novel block copolymer, micelle preparation, and anticancer agent containing the same as active ingredient
WO2006096434A3 (en) Pharmaceutical compositions for the treatment and/or prevention of anxiety disorders
IL184065A (en) Tetrahydroquinoline analogues, uses thereof in the preparation of medicaments and pharmaceutical compositions comprising same
WO2011076749A3 (en) Solid pharmaceutical dosage form of ticagrelor
WO2007146248A3 (en) Stable laquinimod preparations
IL206952A (en) Aminodihydrothiazine derivatives, pharmaceutical compositions comprising them and use thereof in the preparation of medicaments
WO2006131591A3 (en) An entacapone-containing oral dosage form
EP2308870A3 (en) 2-oxo-1-pyrrolidine deriatives, processes for preparing them and their uses
IL208355A (en) 3,7-dihydropurine-2,6-dione derivatives, processes for their preparation, pharmaceutical compositions comprising them and use thereof in the preparation of medicaments
IL194699A (en) Tetrahydropteridines, compositions comprising them and use thereof in the preparation of medicaments
WO2010021607A3 (en) Pharmaceutical formulation
WO2012068441A3 (en) Intedanib salts and solid state forms thereof
WO2006136580A3 (en) 2-(phenylamino)benzimidazole derivatives and their use as modulators of small-conductance calcium-activated potassium channels
IL201730A (en) Derivatives of 1h-benzoimidazol-2-yl-propyl-methyl-amino-ethyl-5-aryl-bicyclo[2.2.2]oct-5-en-2-ol, pharmaceutical compositions comprising them and their use in the manufacture of medicaments
EP1637167A3 (en) New injectable formulations containing progesterone
EP2644614A3 (en) Solid state forms of 5-azacytidine and processes for preparation thereof
WO2007025146A3 (en) Balsalazide formulations and manufacture and use thereof
WO2006054182A3 (en) Phosphoindoles as hiv inhibitors
IL207972A (en) Pyridin-2-yl derivatives, pharmaceutical compositions comprising them and their use in the preparation of medicaments

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08766731

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 08766731

Country of ref document: EP

Kind code of ref document: A2